As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of BeOne Medicines Ltd. The largest reported stake is Baker Bros. Advisors LP's, at 7.8%. 4 filings are on record since April 16, 2026 (Schedule 13D/A, September 16, 2026).
Who owns BeOne Medicines Ltd.?
Sell to companies like BeOne Medicines Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Baker Bros. Advisors LP · Sole voting: 115,457,154 · Shared voting: 0 · Sole dispositive: 115,457,154 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-09-16
- · Holder: Baker Bros. Advisors LP · Percent: 8% · SCHEDULE 13D/A
- · Holder: Capital International Investors · Percent: 4.2% · SCHEDULE 13G/A
- · Holder: Baker Bros. Advisors LP · Percent: 8% · SCHEDULE 13D/A
BeOne Medicines Ltd. has 4 Schedule 13D or 13G filings on record since 2026-04-16. 1 holder's latest filing reports 5% or more of ordinary shares, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 7.8% | 115,457,154 | SCHEDULE 13D/A, 2026-09-16 | 2026-09-14 |
| Capital International Investors | 4.2% | 65,211,266 | SCHEDULE 13G/A, 2026-05-14 | 2026-03-31 |
Holding shares or following this stake? See who's behind BeOne Medicines Ltd. and the warning signs.
Free to see. No signup.
Keep reading
More on BeOne Medicines Ltd. and the records around it.
BeOne Medicines Ltd. elsewhere on the record
Companies that share a holder
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), Cerus Corporation (Aug 2026)
- Capital International Investors also filed stake reports on 96 other companies: Aurora Innovation, Inc. (Nov 2026), Arxis, Inc. (Aug 2026), Astronics Corp. (Aug 2026)
Watch BeOne Medicines Ltd.
Get an email when BeOne Medicines Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on BeOne Medicines Ltd.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on BeOne Medicines Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BeOne Medicines Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 115,457,154 | 0 | 115,457,154 | 0 | SCHEDULE 13D/A, 2026-09-16 |
| Baker Bros. Advisors (GP) LLC | 115,457,154 | 0 | 115,457,154 | 0 | SCHEDULE 13D/A, 2026-09-16 |
| Julian C. Baker | 115,912,814 | 0 | 115,912,814 | 0 | SCHEDULE 13D/A, 2026-09-16 |
| Felix J. Baker | 115,912,814 | 0 | 115,912,814 | 0 | SCHEDULE 13D/A, 2026-09-16 |
| Fbb3 LLC | 144,517 | 0 | 144,517 | 0 | SCHEDULE 13D/A, 2026-09-16 |
The latest filing identifies BeOne Medicines Ltd. by CUSIP 07725L102 and gives its principal executive office as c/o BeOne Medicines I GmbH, Aeschengraben 27, 21st Floor, Basel (SCHEDULE 13D/A, 2026-09-16).
Source of funds (Item 3)
Item 3 of this Schedule 13D is supplemented and amended, as the case may be, as follows: The disclosure in Item 4 below is incorporated herein by reference.Baker Bros. Advisors LP, SCHEDULE 13D/A, 2026-09-16
Purpose of Transaction (Item 4)
Baker Bros. Advisors LP
Item 4 of this Amendment is supplemented and amended, as the case may be, as follows: On September 14, 2026, the Adviser exercised options to purchase Ordinary Shares or ADS ("Share Options") to purchase 30,768 ADS as a result of the exercise of 15,384 Share Options to purchase ADS at $36.83 per ADS (the "Exercised ADS Options") held directly by each of Ranjeev Krishana and Michael Goller, resulting in the acquisition of a total of 30,768 ADS. Messrs. Krishana and Goller, each of whom is a full-time employee of the Adviser, previously served on the Issuer's board of directors (the "Board") as representatives of the Funds. The policy of the Funds and the Adviser does not permit full-time employees of the Adviser to receive compensation for serving as directors of the Issuer, and the Funds are instead entitled to the pecuniary interest in the Exercised ADS Options and any resulting ADS. Messrs. Krishana and Goller, as agents in their capacity as former directors of the Issuer, entered into proceeds agreements (respectively, the "Krishana Proceeds Agreement" and the "Goller Proceeds Agreement" and, collectively, the "Proceeds Agreements") with the Adviser on September 14, 2026. Pursuant to the Proceeds Agreements, Messrs. Krishana and Goller each agreed that, with respect to the Exercised ADS Options and the ADS received as a result of the exercise of the Exercised ADS Options, the Adviser will have dispositive power as well as the ability to control the timing of exercise …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-09-16; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-04-16 | Baker Bros. Advisors LP | 8% | SCHEDULE 13D/A |
| 2026-05-14 | Capital International Investors | 4.2% | SCHEDULE 13G/A |
| 2026-06-15 | Baker Bros. Advisors LP | 8% | SCHEDULE 13D/A |
| 2026-09-16 | Baker Bros. Advisors LP | 7.8% | SCHEDULE 13D/A |
Questions about who owns BeOne Medicines Ltd.
Who owns BeOne Medicines Ltd.?
On this page, one holder's latest ownership filing reports 5% or more of BeOne Medicines Ltd.: Baker Bros. Advisors LP (7.8%, Schedule 13D/A, filed 2026-09-16).
When did Baker Bros. Advisors LP buy into BeOne Medicines Ltd.?
The filings give report dates, not purchase dates. The earliest filing from Baker Bros. Advisors LP on this page is the Schedule 13D/A, filed 2026-04-16, reporting 8%; its latest, Schedule 13D/A filed 2026-09-16, reports 7.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for BeOne Medicines Ltd.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 11, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for BeOne Medicines Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.